Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever.

Authors:
Sener S; Cam V; Batu ED; Kasap Cuceoglu M; Balik Z and 5 more

Journal:
Rheumatology (Oxford)

Publication Year: 2023

DOI:
10.1093/rheumatology/kead128

PMCID:
PMC10629778

PMID:
36961326

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Rheumatology (Oxford)

Abbreviation: Rheumatology (Oxford)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accelerated atherosclerosis in systemic lupus erythematosus: don't forget the devil we know!
van Leuven SI; Major AS. (2024) - Transparency Score: 3/6
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis.
Şahin N; Sönmez HE; Aktay Ayaz N and 1 more (2024) - Transparency Score: 3/6
Adherence to dietary guidelines, and the risk of developing rheumatoid arthritis: results from a ne…
Bäcklund RT; Drake I; Bergström U and 3 more (2024) - Transparency Score: 3/6
A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).
Lioté F; Constantin A; Dahan É and 3 more (2024) - Transparency Score: 4/6
Autoimmune diseases exhibit shared alterations in the gut microbiota.
Wang T; Sternes PR; Guo XK and 3 more (2024) - Transparency Score: 5/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure statement: E.D.B. received payment for speaker’s bureaus from Novartis. S.O. received consultancy fees and payments for speaker’s bureaus from Novartis and Sobi. All other authors declared no conflicts of interest."

Evidence found in paper:

"Funding No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. Disclosure statement: E.D.B. received payment for speaker’s bureaus from Novartis. S.O. received consultancy fees and payments for speaker’s bureaus from Novartis and Sobi. All other authors declared no conflicts of interest."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025